We recently published a list of Here’s What Fueled These 10 Firms’ Surge. In this article, we are going to take a look at where Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stands against other Tuesday’s best-performing stocks. The stock market ended the trading session in the red on Tuesday, with all major indices giving up earlier gains, as investors sold off positions while waiting for the results of the Federal Reserve’s policy decision, while digesting President Donald Trump’s new tariff policies. Among all the major indices, the Dow Jones fell the heaviest, down 0.95 percent. The tech-heavy Nasdaq followed with a 0.87-percent decline, while the S&P 500 finished with a 0.77-percent drop. Beyond the major indices, 10 firms stood out with strong gains amid a flurry of fresh developments, including new partnerships, optimistic outlooks, and impressive earnings performance. In this article, we name Tuesday’s 10 best-performing stocks and detail the reasons behind their gains. To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume.Why Neurocrine Biosciences, Inc. (NBIX) Skyrocketed On Tuesday A healthcare professional discussing treatment options for a patient with a neurological disorder. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Neurocrine Biosciences extended its winning streak for a third day on Tuesday, adding 8.36 percent to finish at $118.92 apiece as optimistic outlooks from two investment firms buoyed investor sentiment. On Tuesday, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) received a “buy” recommendation from Needham & Company alongside a price target of $139, higher than the $138 as projected previously. The new price marked a 16.9-percent upside from its latest closing price. According to Needham, its rating adjustment reflected its positive outlook for Ingrezza, the biopharmaceutical firm’s flagship product for the treatment of tardive dyskinesia. In its latest earnings release, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) said that sales from Ingrezza exceeded expectations during the first quarter of the year, ending at $545 million versus the $525 million the company targeted earlier. In another related development, BofA Securities also raised its price target to $183 from $179 previously and maintained its “buy” recommendation on the stock. Overall, NBIX ranks 9th on our list of Tuesday’s best-performing stocks. While we acknowledge the potential of NBIX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than NBIX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. Story Continues READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. View Comments
Why Neurocrine Biosciences, Inc. (NBIX) Skyrocketed On Tuesday
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...